|
Market Closed -
NYSE
04:00:00 2026-08-18 pm EDT
|
5-day change | 1st Jan Change | ||
| 3.210 USD | -0.31% |
|
+0.94% | +16.73% |
| Aug. 14 | BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 | MT |
| Aug. 11 | Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says | MT |
Company Valuation: Perspective Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.03 | 35.12 | 112.8 | 215.6 | 204.4 | 366.4 | - | - |
| Change | - | -36.19% | 221.19% | 91.16% | -5.18% | 79.24% | - | - |
| Enterprise Value (EV) 1 | 55.03 | 35.12 | 112.8 | -8.207 | 61.26 | 199.9 | 135.6 | 203.9 |
| Change | - | -36.19% | 221.19% | -107.28% | 846.48% | 226.27% | -32.17% | 50.41% |
| P/E | -12.9x | -4.94x | -2.36x | -2.59x | -1.96x | -3.13x | -2.9x | -3.07x |
| PBR | - | - | - | 0.78x | 0.99x | 1.55x | 1.5x | 1.74x |
| PEG | - | -0.1x | -0x | 0.1x | -0.1x | 0.1x | -0.36x | 0.55x |
| Capitalization / Revenue | 5.47x | 9.89x | 78.7x | 148x | 231x | 1,092x | 925x | 27.3x |
| EV / Revenue | 5.47x | 9.89x | 78.7x | -5.64x | 69.3x | 596x | 342x | 15.2x |
| EV / EBITDA | -19.1x | - | - | 0.13x | -0.56x | -1.6x | -0.98x | -1.41x |
| EV / EBIT | -16x | - | -2.75x | 0.12x | -0.54x | -1.63x | -0.94x | -1.4x |
| EV / FCF | - | - | -2.97x | 0.11x | -0.64x | -1.8x | -0.93x | -1.32x |
| FCF Yield | - | - | -33.7% | 886% | -155% | -55.6% | -108% | -75.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.5 | -1.7 | -1.23 | -1.4 | -1.025 | -1.107 | -1.044 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.05 | 3.552 | 1.434 | 1.454 | 0.884 | 0.3355 | 0.3962 | 13.44 |
| EBITDA 1 | -2.874 | - | - | -64.49 | -110.3 | -124.5 | -139 | -144.5 |
| EBIT 1 | -3.446 | - | -40.94 | -66.8 | -113.6 | -122.8 | -143.7 | -145.4 |
| Net income 1 | -3.39 | - | -46.51 | -79.28 | -103.1 | -115.2 | -137 | -138.6 |
| Net Debt 1 | - | - | - | -223.8 | -143.2 | -166.6 | -230.9 | -162.5 |
| Reference price 2 | 3.878 | 2.471 | 4.020 | 3.190 | 2.750 | 3.210 | 3.210 | 3.210 |
| Nbr of stocks (in thousands) | 14,192 | 14,211 | 28,057 | 67,588 | 74,338 | 114,152 | - | - |
| Announcement Date | 9/21/21 | 5/1/23 | 3/28/24 | 3/26/25 | 3/16/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.14x | 599.23x | -1.61x | -.--% | 368M | |
| 33.26x | 5.94x | 17.67x | 0.96% | 48.84B | |
| -22x | 301.52x | -22.38x | -.--% | 45.44B | |
| 47.49x | 5.5x | 30.07x | -.--% | 41.22B | |
| 31.07x | 3.07x | 13.27x | -.--% | 39.71B | |
| 30.58x | 8.82x | 22.17x | 0.38% | 32.6B | |
| 33.96x | 5.56x | 25.28x | -.--% | 16.67B | |
| 23.34x | 2.04x | 8.84x | 1.15% | 14.08B | |
| 76.69x | 4.04x | 15.66x | -.--% | 13.68B | |
| Average | 27.92x | 103.97x | 12.11x | 0.28% | 28.07B | |
| Weighted average by Cap. | 26.74x | 59.48x | 12.25x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CATX Stock
- Valuation Perspective Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
